Celularity, Inc. (CELU) vs Sangamo Therapeutics, Inc. (SGMOQ)

Celularity, Inc. and Sangamo Therapeutics, Inc. are both Biotechnology companies. Celularity, Inc. and Sangamo Therapeutics, Inc. are of similar size ($41.9M and $38.2M). Sangamo Therapeutics, Inc. grew revenue faster over the last twelve months: −45.8% against −51.0%. Celularity, Inc. has the higher net margin (−345.8% vs −356.9%) and the lower return on invested capital (−1,070.9% vs 0.00%). Across the 17 metrics below, Celularity, Inc. leads on 10 and Sangamo Therapeutics, Inc. on 7.

Valuation

Metric CELU SGMOQ Biotechnology median
P/E n/m n/m 7.88
P/S 1.33 1.58 11.47
P/B n/m n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 2.90 1.79 10.73
Earnings yield (259.89%) (271.43%) (28.84%)
Free cash flow yield (37.97%) (165.83%) (23.03%)

Profitability

Metric CELU SGMOQ Biotechnology median
Gross margin 24.39% 100.00% 65.16%
Operating margin (230.92%) (357.55%) 0.00%
Net margin (345.76%) (356.89%) 0.00%
Free cash flow margin (49.92%) (261.76%) 0.00%
Return on equity 628.23% 1,755.72% (57.72%)
Return on assets (76.50%) (168.79%) (49.22%)
Return on invested capital (1,070.92%) 0.00% 0.00%

Growth

Metric CELU SGMOQ Biotechnology median
Revenue growth (TTM) (51.03%) (45.80%) 5.64%
EPS growth (last fiscal year) (35.71%) 10.20% —
Revenue growth, 5-year CAGR 13.21% (19.66%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CELU SGMOQ Biotechnology median
Debt to equity (1.26) 0.00 0.00
Current ratio 0.15 0.70 4.73
Net debt to EBITDA (0.77) 0.18 0.96

Dividend

Metric CELU SGMOQ Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CELU SGMOQ Biotechnology median
Market cap 38.21m 41.89m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack